US2016031975A1PendingUtilityA1
Compositions and Methods for Antibodies Targeting Complement Protein C5
Est. expiryAug 5, 2028(~2.1 yrs left)· nominal 20-yr term from priority
Inventors:Beate Diefenbach-StreiberAdina EberthBraydon Charles GuildYong-In KimMichael RoguskaIgor Splawski
A61P 7/00C07K 2317/92C07K 2317/24C07K 2317/622C07K 16/18C07K 2317/76C07K 2317/55C07K 2317/21C07K 2317/565C07K 2317/14A61K 39/395
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
Claims
exact text as granted — not AI-modified1 - 16 . (canceled)
17 . An isolated antibody, or an antigen binding fragment thereof, comprising a heavy chain variable region having the sequence of SEQ ID NO: 7 and a light chain variable region having the sequence of SEQ ID NO: 8.
18 . The antibody, or an antigen binding fragment thereof, of claim 17 , wherein said antibody is a monoclonal antibody.
19 . The antibody, or an antigen binding fragment thereof, of claim 18 , wherein said antibody is a human or humanized antibody.
20 . The antibody, or an antigen binding fragment thereof, of claim 18 , wherein said antibody is a chimeric antibody.
21 . The antibody, or an antigen binding fragment thereof, of claim 18 , wherein said antibody comprises a human heavy chain constant region and a human light chain constant region.
22 . The antibody, or an antigen binding fragment thereof, of claim 18 , wherein said antibody is a single chain antibody.
23 . The antibody, or an antigen binding fragment thereof, of claim 18 , wherein said antibody is a Fab fragment.
24 . The antibody, or an antigen binding fragment thereof, of claim 18 , wherein said antibody is a scFv.
25 . The antibody, or an antigen binding fragment thereof, of claim 18 binds to both human complement C5 and cynomolgus complement C5.
26 . The antibody of claim 18 , or an antigen binding fragment thereof, is an IgG isotype.
27 . The antibody, or an antigen binding fragment thereof, of claim 17 , wherein said antibody comprises a heavy chain having the sequence of SEQ ID NO: 9 and a light chain having the sequence of SEQ ID NO: 10.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.